

## Roadshow – Edinburgh



Edinburgh, 8 September 2017

## Safe Harbor Statement

---

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

# A Global Leader In HealthCare Products And Services

---



---

**~€29.5 bn in Sales**  
(as of Dec. 31, 2016)

---

---

**Strong portfolio  
of products** (30% of sales)  
**and services** (70% of sales)

---

---

**Total Shareholder Return:  
10-year CAGR: ~17%**

---

---

**Global presence in  
100+ countries**


---

---

**260,000+ employees  
worldwide**  
(as of June 30, 2017)

---

# Strong, Diversified Product And Service Portfolio



Ownership: 31%

Dialysis Products  
Healthcare Services

**Sales 2016: €16.6 bn**



Ownership: 100%

Hospital Supplies  
and Services

**Sales 2016: €6.0 bn**



Ownership: 100%

Hospital Operations

**Sales 2016: €5.8 bn**

**Sales 2016 pro-forma  
Quirónsalud: ~€8.4 bn**




Ownership: 77%

Hospital Projects  
and Services


**Sales 2016: €1.2 bn**

# Total Shareholder Return – CAGR, rounded


## 15 years



## 10 years




## 5 years




Source: Bloomberg; dividends reinvested

# Fresenius Group Consistent Cash Generation And Proven Track Record of Deleveraging


## CFFO margin




## FCF margin (before acquisitions & dividends)



## Capex gross, in % of sales



## Net Debt / EBITDA<sup>1,2</sup>



<sup>1</sup> At actual FX rates for both Net Debt and EBITDA

<sup>2</sup> Pro Forma acquisitions, before special items

# Fresenius Medical Care: Global Dialysis Market Leader

- The world's leading provider of dialysis products and services treating 315,305 patients<sup>1</sup> in 3,690 clinics<sup>1</sup>
- Provide highest standard of product quality and patient care

---

 Dialysis products

---

 Dialysis services

---

 Complete therapy offerings

---

- Expansion in Care Coordination and global dialysis service opportunities; enter new geographies

## Market Dynamics

### Global Dialysis Market 2016:

- ~US\$76 bn
- ~6% patient growth p.a.

### Growth Drivers:

- Aging population, increasing incidence of diabetes and high blood pressure, treatment quality improvements



<sup>1</sup> As of June 30, 2017

# Fresenius Kabi: A Leading Global Hospital Supplier

- Comprehensive product portfolio for critically and chronically ill patients
- Strong Emerging Markets presence
- Leading market positions in four product segments



Generic IV Drugs



Clinical Nutrition



Infusion Therapy



Medical Devices /  
Transfusion Technology

- Focus on organic growth through geographic product rollouts and new product launches


## Market Dynamics

### Global Addressable Market 2016:

- >€48 bn

### Growth Drivers:

- Patent expirations, rising demand for health care services, higher health care spending in Emerging Markets





# Fresenius Helios: Europe's largest private hospital operator

## Helios Kliniken Germany

- ~6% share in German acute care hospital market
- Solid organic growth based on growing number of admissions and reimbursement rate increases
- Strong track record in hospital acquisitions and operation
- Ranks as quality leader in the German hospital sector: defined quality targets, publication of medical treatment results, peer review processes
- Key medical indicators, e.g. mortality rate for heart failure, pneumonia below German average

### Market Dynamics

#### German Acute Care Hospital Market:

- ~€94 bn<sup>1</sup>

#### Growth Drivers:

- Aging population leading to increasing hospital admissions, further market consolidation

### Largest network & nationwide presence



112 hospitals  
 ~35,000 beds  
 ~1.3 million inpatient admissions p.a.  
 ~3.9 million outpatient admissions p.a.

As of June 30, 2017

 Acute Care

 Rehab

 Outpatient

<sup>1</sup> German Federal Statistical Office 2016; total costs, gross of the German hospitals less academic research and teaching

# Fresenius Helios: Europe's largest private hospital operator

## Quirónsalud Spain

- ~€2.5bn sales in 2016
- ~10% share in Spanish private hospital market
- Market leader in size and quality with excellent growth prospects
- Broad revenue base with privately insured patients, PPPs, self-pay and Occupational Risk Prevention (ORP)
- Strong management team with proven track record
- Cross-selling opportunities



Acute Care



Outpatient



Occupational Risk Prevention

### Market Dynamics

#### Spanish Private Hospital Market:

- ~€13 bn<sup>1</sup>

#### Growth Drivers:

- Aging population, increasing number of privately insured patients, greenfield projects, market consolidation

#### Quirónsalud hospitals in every major metropolitan region of Spain



44 hospitals  
6,600 beds  
~ 9.4 m outpatient admissions p.a.  
~ 320,000 inpatient admissions p.a.

As of June 30, 2017

<sup>1</sup> Market data based on company research. Market definition does neither include Public Private Partnerships (PPP) nor Occupational Risk Prevention centers (ORP).

# Fresenius Vamed: Leading Global hospital Projects And Services Specialist

---

- Manages hospital construction/expansion projects (51% of sales) and provides services (49% of sales) for health care facilities worldwide



Projects



Services

---

- Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
- Strong track record: More than 800 projects in 79 countries completed


## Market Dynamics

### Growth Drivers:

- Emerging Market demand for building and developing hospital infrastructure
- Outsourcing of non-medical services from public to private operators

---




Emerging Markets  
29%



---

Europe 71%

# Fresenius Group: 2017 Financial Outlook by Business Segment

€m except otherwise stated		2016 Base	2017e Previous	H1/17 Actual	2017e New
 <b>FRESENIUS KABI</b>	<b>Sales growth (org)</b>	6,007	5% – 7%	7%	☑
	<b>EBIT growth (cc)</b>	1,171	6% – 8% <sup>1</sup>	6% <sup>5</sup>	☑
 <b>FRESENIUS HELIOS</b>	<b>Sales growth (org)</b>	5,843 <sup>2</sup>	3% – 5% <sup>2</sup>	4% <sup>2</sup>	☑
	<b>Sales (reported)</b>	5,843 <sup>2</sup>	~8.6bn <sup>3</sup>	4.3bn	☑
	<b>EBIT</b>	683 <sup>2</sup>	1,020–1,070 <sup>4</sup>	537	☑
 <b>FRESENIUS VAMED</b>	<b>Sales growth (org)</b>	1,160	5% – 10%	2%	☑
	<b>EBIT growth</b>	69	5% – 10%	6%	☑

<sup>1</sup> Before transaction costs of ~€50 million for the acquisitions of Akorn, Inc. and Merck KGaA's biosimilars business; before expected expenditures for the further development of Merck KGaA's biosimilars business of ~€60 million

<sup>2</sup> HELIOS Kliniken Germany, excluding Quirónsalud


<sup>3</sup> Thereof Quirónsalud (11 months consolidated): ~€2.5bn

<sup>4</sup> Thereof Quirónsalud (11 months consolidated): €300 to €320m

<sup>5</sup> Before special items

All data according to IFRS

# Fresenius Group: 2017 Financial Guidance

€m except otherwise stated		2016 Base	2017e Previous	H1/17 Actual	2017e New
 <b>FRESENIUS</b>	<b>Sales growth (cc)</b>	29,471	15% – 17%	17%	<input checked="" type="checkbox"/>
	<b>Net income<sup>1</sup> growth (cc)</b>	1,560	19% – 21% <sup>2</sup>	23% <sup>3</sup>	<input checked="" type="checkbox"/>

<sup>1</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

<sup>2</sup> Before transaction costs of –€50 million for the acquisitions of Akorn, Inc. and Merck KGaA's biosimilars business; before expected expenditures for the further development of Merck KGaA's biosimilars business of ~€60 million


<sup>3</sup> Before special items

All data according to IFRS

# Fresenius Group: Ambitious Mid-Term Targets


## Sales

€bn



## Net Income

€m



<sup>1</sup> Mid-point of the February 2017 sales guidance, adjusted for exchange rates as of February 2017

<sup>2</sup> Mid-point of the February 2017 net income guidance, adjusted for exchange rates as of February 2017

<sup>3</sup> Calculated on the basis of the mid-point of the 2020 target range

At February 2017 exchange rates; excluding strategic acquisitions; at current IFRS rules

# Fresenius Kabi: Update Acquisition Projects



- No change in 2018 expectations<sup>1</sup>
- Transaction offers offensive and defensive merits
- Akorn shareholders approved merger agreement with vast majority
- Closing targeted for 2017



- Closing 31 August 2017
- Improving regulatory environment
- Product pipeline: All studies well on track
- Adalimumab: Filing for European approval expected for Q4/17



<sup>1</sup> Assuming the transaction closes at the end of 2017, Fresenius Kabi projects 2018 sales from this business of US\$1,035 to 1,085 million, and EBITDA before integration costs of approximately US\$380 to 420 million.

## Fresenius Group: Q2/17 Highlights

---

---

 **Strong sales growth across all business segments**

---

 **Ongoing excellent earnings growth**

---

 **Group guidance confirmed**

---

 **Quirónsalud fully in line with expectations**


---

 **Rachel Empey appointed as Group CFO**

---




# Fresenius Group: Q2/17 Key Financials



Constant currency growth rates (cc)  
EBIT and net income before special items  
Net income attributable to shareholders of Fresenius SE & Co. KGaA

# Fresenius Group: Q2/17 Business Segment Growth



<sup>1</sup> Excluding the agreement with the United States Departments of Veterans Affairs and Justice at Fresenius Medical Care

<sup>2</sup> Before special items

# Fresenius Kabi: Q2/17 Regional Highlights (1/2)

---

## North America

- 9% organic sales growth
- 17 Kabi-marketed IV drugs currently designated in shortage (vs. 15 at Q1/17)
- 4 product launches YTD; confirm 10+ target
- Confirm FY/17 outlook: mid-single-digit organic sales growth



## Europe

- 4% organic sales growth
- Confirm FY/17 outlook: low to mid-single-digit organic sales growth



# Fresenius Kabi: Q2/17 Regional Highlights (2/2)

## Emerging Markets

### China

- 12% organic sales growth
- New tender rules:
  - 16 of 31 provinces have concluded a tender process; introduction of new tender policy expected to be mostly completed end of 2017
  - Expect low to mid single-digit price impact in FY/17
  - Continued double-digit volume growth projected

Asia-Pacific ex China: 6% organic sales growth

Latin America/Africa: 8% organic sales growth despite tough comp



### Total Emerging Markets

Confirm FY/17 outlook: at least 10% organic sales growth



## Fresenius Kabi: Organic Sales Growth by Regions

€m	Q2/17	Δ YoY organic	H1/17	Δ YoY organic
Europe	553	4%	1,097	6%
North America	568	9%	1,187	6%
<i>Asia-Pacific</i>	<i>302</i>	<i>10%</i>	<i>582</i>	<i>10%</i>
<i>Latin America/Africa</i>	<i>175</i>	<i>8%</i>	<i>336</i>	<i>11%</i>
Asia-Pacific/Latin America/Africa	477	10%	918	10%
<b>Total sales</b>	<b>1,598</b>	<b>7%</b>	<b>3,202</b>	<b>7%</b>

## Fresenius Kabi: Organic Sales Growth by Product Segment

€m	Q2/17	Δ YoY organic	H1/17	Δ YoY organic
IV Drugs	680	10%	1,382	8%
Infusion Therapy	228	4%	455	7%
Clinical Nutrition	420	8%	827	8%
Medical Devices/ Transfusion Technology	270	3%	538	5%
<b>Total sales</b>	<b>1,598</b>	<b>7%</b>	<b>3,202</b>	<b>7%</b>

## Fresenius Kabi: Q2 & H1/17 EBIT Growth

€m	Q2/17	Δ YoY cc	H1/17	Δ YoY cc
Europe Margin	84 15.2%	0% -50 bps	164 14.9%	1% -50 bps
North America Margin	220 38.7%	11% 90 bps	456 38.4%	4% -70 bps
Asia-Pacific/Latin America/Africa Margin	86 18.0%	5% -130 bps	172 18.7%	15% 10 bps
Corporate and Corporate R&D	-81	2%	-170	-5%
<b>Total EBIT Margin</b>	<b>309</b> 19.3%	<b>9%</b> 40 bps	<b>622</b> 19.4%	<b>6%</b> -40 bps

Before special items  
Margin growth at actual rates

For a detailed overview of special items please see the reconciliation tables on slides 26-27.


# Fresenius Helios: Q2 & H1/17 Highlights

## HELIOS Kliniken

- Wage contracts in place for medical and non-medical employees until end of 2018; average increase of ~2.5% p.a., in line with budget assumptions
- New proton beam therapy center for Berlin-Buch projected, scheduled opening 2021

### Sales

€m



## Quirónsalud

- 11% sales growth in H1/17
- EBIT growth exceeds sales growth; synergies of merger between IDCsalud and Quirón provide tailwind
- Typical summer slump will impact Q3/17 result





## Fresenius Helios: Q2 & H1/17 Key Financials

€m	Q2/17	Δ YoY	H1/17	Δ YoY
<b>Total sales</b>	<b>2,238</b>	<b>52%</b>	<b>4,256</b>	<b>46%</b>
Thereof HELIOS Kliniken	1,510	2%	3,038	4%
Thereof Quirónsalud	728	--	1,218	--
<b>Total EBIT</b>	<b>282</b>	<b>63%</b>	<b>537</b>	<b>62%</b>
Margin	12.6%	90 bps	12.6%	120 bps
Thereof HELIOS Kliniken	178	3%	359	8%
Margin	11.8%	10 bps	11.8%	40 bps
Thereof Quirónsalud	104	--	178	--
Margin	14.3%	--	14.6%	--

# Quirónsalud: Integration Status and Growth Prospects

---

## Integration process

- Procurement analysis phase successfully completed; implementation phase commenced (e.g. lab disposables)
- Openness to learn from the best e.g. compare experience on medical practices

## Growth prospects

- €50m greenfield investment project in Córdoba Andalusia on track:
  - 115 bed hospital provides state-of-the-art medical equipment and care
  - Opening expected for June 2018
- €31m hospital expansion in Pozuelo, Madrid
  - 2 additional operating theatres, 25 new examination rooms, 7 additional intensive care beds, new state-of-the-art MRI

## Strong position

- PPP contracts in place up to 2041
- Four Quirónsalud hospitals ranked in Top 10 of Hospital Excellence Index (HEI)



# Fresenius Vamed: Q2 & H1/17 Highlights

- 2% sales growth in Q2/17 reflects typical quarterly fluctuations of project business
- Solid order intake; order backlog at all-time high
- New projects in Papua New Guinea and Mongolia








€m	Q2/17	Δ YoY	H1/17	Δ YoY
Project business	107	-3%	184	-6%
Service business	151	5%	297	7%
<b>Total sales</b>	<b>258</b>	<b>2%</b>	<b>481</b>	<b>2%</b>
<b>Total EBIT</b>	<b>11</b>	<b>22%</b>	<b>17</b>	<b>6%</b>
Order intake <sup>1</sup>	192	-16%	412	-11%
Order backlog <sup>1</sup>			2,188	12% <sup>2</sup>

<sup>1</sup> Project business only

<sup>2</sup> Versus December 31, 2016

# Fresenius Group: Q2/17 & LTM Cash Flow

€m	Operating CF		Capex (net)		Free Cash Flow <sup>1</sup>	
	Q2/17	LTM Margin	Q2/17	LTM Margin	Q2/17	LTM Margin
 <b>FRESENIUS KABI</b>	203	16.9%	-82	-5.9%	121	11.0%
 <b>FRESENIUS HELIOS</b>	120	9.7%	-79	-5.2%	41	4.5% <sup>3</sup>
 <b>FRESENIUS VAMED</b>	16	-0.2%	2	-0.5%	18	-0.7%
<b>Corporate/Other</b>	-14	n.a.	-5	n.a.	-19	n.a.
 <b>FRESENIUS</b> Excl. FMC	<b>325</b>	<b>12.4%</b> <sup>2</sup>	<b>-164</b>	<b>-5.2%</b>	<b>161</b>	<b>7.2%</b> <sup>2</sup>
 <b>FRESENIUS</b>	<b>1,207</b>	<b>12.2%</b>	<b>-357</b>	<b>-5.0%</b>	<b>850</b>	<b>7.2%</b>

<sup>1</sup> Before acquisitions and dividends


<sup>2</sup> Margin incl. FMC dividend

<sup>3</sup> Understated: 5.0% excluding €36 million of capex commitments from acquisitions

## Fresenius Group: Cash Flow

€m	Q2/17	LTM Margin	Q2/16	LTM Margin	Δ YoY
<b>Operating Cash Flow</b>	<b>1,207</b>	<b>12.2 %</b>	<b>997</b>	<b>12.0%</b>	<b>21%</b>
Capex (net)	-357	-5.0%	-350	-5.5%	-2%
<b>Free Cash Flow</b> (before acquisitions and dividends)	<b>850</b>	<b>7.2%</b>	<b>647</b>	<b>6.5%</b>	<b>31%</b>
Acquisitions (net)	-380		-68		
Dividends	-722		-545		
<b>Free Cash Flow</b> (after acquisitions and dividends)	<b>-252</b>	<b>-14.6%</b>	<b>34</b>	<b>3.1%</b>	<b>--</b>

# Fresenius Group: Leverage Ratio




<sup>1</sup> Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG

<sup>2</sup> Pro forma acquisitions of Akorn, Inc. and Merck KGaA's biosimilars business; before transaction costs of ~€50 million; excluding further potential acquisitions

Before special items; pro forma acquisitions

At annual average FX rates for both EBITDA and net debt

# Fresenius Group Debt Maturity Profile<sup>1</sup>



<sup>1</sup> March 31, 2017; based on utilization of major financing instruments

# Acquisition of Akorn & Merck KGaA's Biosimilars Business





# Safe Harbor Statement

---

## **THIS PRESENTATION IS FOR INFORMATION PURPOSES ONLY.**

This presentation does not constitute or form part of, and should not be construed as, any offer or invitation to subscribe for, underwrite or otherwise acquire, any securities of Fresenius SE & Co. KGaA ("Fresenius") or any present or future member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities in Fresenius or any member of its group or any commitment whatsoever.

In particular, this presentation is not an offer of securities in the United States of America (including its territories and possessions), and securities of Fresenius may not be offered or sold in the United States of America absent registration under the Securities Act of 1933 (which Fresenius does not intend to effect) or pursuant to an exemption from registration.

The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements contained in this presentation may be statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, as well as the words "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements as a result of, among other factors, changing business or other market conditions and the prospects for growth anticipated by the management of Fresenius. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Fresenius does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

# Akorn: Transaction Highlights

---



**Complementary product portfolio and pipeline diversifies Fresenius Kabi's IV generics offering**



**Access to additional distribution channels: retail, clinics and physicians**



**Adds growth potential in attractive adjacent segments such as ophthalmology and clinical dermatology**



**Substantial cost and growth synergies paired with limited integration complexity**



**Fully debt-financed**



**Accretive to Group net income<sup>1</sup> from 2018**



<sup>1</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA; before integration costs

## Akorn: Financially Sound Acquisition

---


<b>Cash purchase price</b>	<b>US\$4.30 bn for 100% of Akorn shares (US\$34/share)</b>
<b>Assumed net debt<sup>1</sup></b>	<b>~US\$0.45 bn</b>
<b>Amortization charge</b>	<b>Initially ~US\$130 m p.a.</b>
<b>Synergies</b>	<b>~US\$100 m p.a. before tax mid-term, progressive ramp-up</b>
<b>Integration costs</b>	<b>~US\$140 m before tax in total for 2018 - 2022</b>
<b>Financing</b>	<b>Broad mix of € and US\$ debt instruments at ~4% p.a.</b>
<b>Tax rate</b>	<b>~35%</b>
<b>EPS<sup>2</sup></b>	<b>Accretive in 2018 (excluding integration costs), from 2019 (including integration costs)</b>
<b>Closing</b>	<b>Targeted for 2017</b>

<sup>1</sup> Projected net debt as of December 31, 2017

<sup>2</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

# Akorn: Complementary Product Portfolio and Distribution Channels


## Dosage forms



### Common characteristics

- Mostly sterile
- Non-solid
- Generic
- Specialized manufacturing

## Distribution channels







- Retail**
- Ophthalmics
  - Topicals
  - Oral Liquids
  - Nasal / Inhalation
  - OTC

- Institutional**
- Injectables
  - Ophthalmics
  - Unit Dose
  - Nasal / Inhalation
- Physician**
- Ophthalmics
  - Animal Health


Note: Sales mix based on 2016 data

# Akorn: Diversified U.S. Portfolio

	Current Portfolio		Pipeline	
	 FRESENIUS KABI	 AKORN	 FRESENIUS KABI	 AKORN
<b>Total Products</b>	<b>137</b>	<b>173</b>	<b>55</b>	<b>85</b>
IV Analgesics & Anesthetics	●●●	●	●●	●
IV Anti-Infectives	●●●	●	●	●●
IV Critical Care	●●●	●●	●●●	●●●
IV Oncolytics	●●●	●	●●●	●
Nutrition & IV Solutions	●	●	●●	
<hr/>				
Ophthalmics		●●●		●●●
Topicals		●		●●
Orals	●	●●●		●
Nasal / Otics / Consumer Health		●●		●
Animal Health		●		●

●●● strong    ●● medium    ● light

# Akorn: Concentrated U.S. Footprint



# Akorn: Detailed and Comprehensive Due Diligence

---

## Process

- Bilateral exchange with Akorn since 11/2016
- Very comprehensive due diligence over more than two months covering all functional areas
- Virtual data room, management presentations and expert meetings
- Multiple visits of all manufacturing plants
- Detailed bottom-up business plan
- Internal resources supported by external advisers and specialists in new product areas

## Addressed areas

- ANDA pipeline, related regulatory approvals and R&D costs
- New distribution channels and Akorn's strengths
- Sales practices, pricing history and related customer perception
- Competition in key product areas
- Plant status (technical and regulatory) and future manufacturing strategy
- Serialization readiness
- Accounting issues and internal control systems
- Current trading



# Biosimilars: Transaction Highlights

---

- ✓ **Strategic step to enhance Fresenius Kabi's position as a leading player in the injectable pharmaceuticals market**
- ✓ **Direct access to attractive biosimilars development platform**
- ✓ **Experienced team of biosimilars experts with excellent development know-how**
- ✓ **Highly variable consideration strictly tied to development targets**
- ✓ **EBITDA break-even in 2022**
- ✓ **High triple-digit million sales from 2023 onwards**





## Biosimilars: Sound Risk/Reward Ratio

---

<b>Purchase price</b>	<b>€156 m upfront payment</b>
<b>Milestone payments</b>	<b>Up to €500 m, strictly tied to achievement of development targets</b>
<b>Sales</b>	<b>First sales in 2019, ramp-up to high triple-digit € million from 2023 onwards</b>
<b>Royalties</b>	<b>Single-digit percentage royalties based on sales</b>
<b>EPS<sup>1</sup></b>	<b>Significantly accretive from 2023 onwards</b>
<b>Self-imposed investment ceiling</b>	<b>€1.4 bn incl. upfront and milestone payments as well as ramp-up of R&amp;D and M&amp;S expenses until EBITDA break-even in 2022</b>
<b>Financing</b>	<b>Mainly free cash flow</b>
<b>Closing</b>	<b>31 August 2017</b>

<sup>1</sup> Net income attributable to shareholders of Fresenius SE & Co. KGaA

# Biosimilars: Highly Attractive Platform

---



**Background:** Established in 2012 as a Business Unit within the biopharmaceutical development/production network of Merck KGaA



**Pipeline:** Single-digit number of molecules in oncology and autoimmune diseases




**Organization:** Core team of >70 experts located in Aubonne and Vevey, Switzerland



**Network:** External partners supporting development, documentation and regulatory affairs

Merck Biopharma provides support in manufacturing (one production suite reserved for biosimilars), analytics, regulatory, quality, safety and clinical operations.

# Expanding U.S. Market Access



**GPOs**


**Institutional**



**Clinics & Physicians**



**Retail Pharmacies**




- |                    |   |  |
|--------------------|---|--|
| Injectables        | Others (e.g. Otics, oral liquid, ophthalmics) | <input type="checkbox"/> Good market penetration             |
| Infusion solution  | Biosimilars                                   | <input checked="" type="checkbox"/> Light market penetration |
| Clinical nutrition | Pre-filled syringe                            | <input type="checkbox"/> Not yet marketed                    |
| Medical devices    | Transfusion technology                        |  |

# Who Brings What to a Great Party?



Biosimilars



Global R&D expertise



Quality Mgmt. Scale



Scale



US inst. access  
Global distribution



Alternate dosage forms

Alternate dosage forms

Diverse sales channels

# Financial Calendar / Contact

---

## Financial Calendar 2017

02.11.2017	Report on 3 <sup>rd</sup> quarter 2017
18.05.2018	Annual General Meeting

Please note that these dates could be subject to change.

## Contact

Investor Relations

Fresenius SE & Co. KGaA

phone: +49 6172 608-2485

e-mail: [ir-fre@fresenius.com](mailto:ir-fre@fresenius.com)

For further information and current news: [www.fresenius.com](http://www.fresenius.com)

Follow us on Twitter [www.twitter.com/fresenius\\_ir](http://www.twitter.com/fresenius_ir)

and LinkedIn: [www.linkedin.com/company/fresenius-investor-relations](http://www.linkedin.com/company/fresenius-investor-relations)